PMID- 15322696
OWN - NLM
STAT- MEDLINE
DCOM- 20050628
LR  - 20181201
IS  - 0028-2804 (Print)
IS  - 0028-2804 (Linking)
VI  - 76
IP  - 3
DP  - 2005 Mar
TI  - [Combination treatment with SSRI and cognitive behavior therapy for relapse 
      prevention of alcohol-dependent men. Results of a randomized, controlled 
      multicenter therapeutic study].
PG  - 295-307
AB  - BACKGROUND: This study evaluates the serotonergic antidepressant nefazodone 
      (SSRI) vs placebo (PL) and specific cognitive-behavioral therapy (CBT) vs 
      nondirective group counseling (GC) for relapse prevention in alcohol dependence 
      in a large, prospective, randomized and placebo-controlled, double-blind study at 
      three German university centers. METHODS: Male patients fulfilling at least five 
      criteria for alcohol dependence according to DSM-IV and ICD-10 were eligible, 
      after detoxification, for one of the following treatment combinations: SSRI+CBT, 
      SSRI+GC, PL+CBT, and PL+GC. The SSRI or PL were administered throughout the 
      evaluation period of 15 months. CBT or GC was applied during the first 12 weeks 
      as group therapy according to operationalized manuals. The main outcome measures 
      (assessed at 3 and 12 months of treatment) were the cumulative number of 
      abstinent days, the amount of ethanol consumed during specified evaluation 
      periods of 3 and 12 months, the number of relapses, and the duration of time 
      until first relapse. RESULTS: After 12 weeks of treatment, no statistically 
      significant differences in any outcome measure were observed between the four 
      treatment combinations. After 52 weeks, the only significant difference was 
      observed in the amount of ethanol consumed, with the SSRI+GC group showing higher 
      intake. CONCLUSIONS: The results of this carefully designed clinical trial 
      suggest that the four treatment combinations do not differ substantially in their 
      efficacy in relapse prevention of nondepressed, severely alcohol-dependent 
      patients. Nefazodone may even promote ethanol drinking in a subset of patients. 
      Cognitive-behavioral therapy as performed in this study was associated with 
      little additional benefit compared with structured GC.
FAU - Hautzinger, M
AU  - Hautzinger M
AD  - Psychologisches Institut, Eberhard-Karls-Universitat Tubingen. 
      hautzinger@uni-tuebingen.de
FAU - Wetzel, H
AU  - Wetzel H
FAU - Szegedi, A
AU  - Szegedi A
FAU - Scheurich, A
AU  - Scheurich A
FAU - Lorch, B
AU  - Lorch B
FAU - Singer, P
AU  - Singer P
FAU - Schlafke, D
AU  - Schlafke D
FAU - Sittinger, H
AU  - Sittinger H
FAU - Wobrock, T
AU  - Wobrock T
FAU - Muller, M J
AU  - Muller MJ
FAU - Anghelescu, I
AU  - Anghelescu I
LA  - ger
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Ruckfallverhinderung bei alkoholabhangigen Mannern durch die Kombination von SSRI 
      und kognitiver Verhaltenstherapie. Ergebnisse einer randomisierten 
      kontrollierten, multizentrischen Therapiestudie.
PL  - Germany
TA  - Nervenarzt
JT  - Der Nervenarzt
JID - 0400773
RN  - 0 (Piperazines)
RN  - 0 (Triazoles)
RN  - 59H4FCV1TF (nefazodone)
SB  - IM
MH  - Adult
MH  - Alcoholism/*epidemiology/*prevention & control
MH  - Cognitive Behavioral Therapy/*statistics & numerical data
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Germany/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Piperazines
MH  - Prevalence
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Treatment Outcome
MH  - Triazoles/*administration & dosage
EDAT- 2004/08/24 05:00
MHDA- 2005/06/29 09:00
CRDT- 2004/08/24 05:00
PHST- 2004/08/24 05:00 [pubmed]
PHST- 2005/06/29 09:00 [medline]
PHST- 2004/08/24 05:00 [entrez]
AID - 10.1007/s00115-004-1763-y [doi]
PST - ppublish
SO  - Nervenarzt. 2005 Mar;76(3):295-307. doi: 10.1007/s00115-004-1763-y.